Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
4082431
Reference Type
Journal Article
Title
Biomonitoring Equivalents for molybdenum
Author(s)
Hays, SM; Macey, K; Poddalgoda, D; Lu, M; Nong, A; Aylward, LL
Year
2016
Is Peer Reviewed?
1
Journal
Regulatory Toxicology and Pharmacology
ISSN:
0273-2300
EISSN:
1096-0295
Volume
77
Page Numbers
223-229
Language
English
PMID
26972837
DOI
10.1016/j.yrtph.2016.03.004
Web of Science Id
WOS:000376812900026
Abstract
Molybdenum is an essential trace element for mammalian, plant, and other animal systems. The Institute of Medicine (IOM) has established an Estimated Average Requirement (EAR) to assure sufficient molybdenum intakes for human populations; however excessive exposures can cause toxicity. As a result, several agencies have established exposure guidance values to protect against molybdenum toxicity, including a Reference Dose (RfD), Tolerable Daily Intake (TDI) and a Tolerable Upper Intake Level (UL). Biomonitoring for molybdenum in blood or urine in the general population is being conducted by the Canadian Health Measures Survey (CHMS) and the U.S. National Health and Nutrition Examination Survey (NHANES). Using pharmacokinetic data from controlled human dosing studies, Biomonitoring Equivalents (BEs) were calculated for molybdenum in plasma, whole blood, and urine associated with exposure guidance values set to protect against both nutritional deficits and toxicity. The BEEAR values in plasma, whole blood and urine are 0.5, 0.45 and 22 μg/L, respectively. The BEs associated with toxicity range from 0.9 to 31 μg/L in plasma, 0.8-28 μg/L in whole blood and 200-7500 μg/L in urine. These values can be used to interpret molybdenum biomonitoring data from a nutritional and toxicity perspective.
Keywords
Age Factors; Animals; Biomarkers/blood/urine; Dose-Response Relationship, Drug; Environmental Monitoring/methods; Environmental Pollutants/adverse effects/blood/pharmacokinetics/urine; Models, Biological; Molybdenum/adverse effects/blood/pharmacokinetics/urine; No-Observed-Adverse-Effect Level; Nutritional Status; Recommended Dietary Allowances; Risk Assessment; Species Specificity; Trace Elements/adverse effects/blood/pharmacokinetics/urine; Biomonitoring; Biomonitoring Equivalents; Molybdenum
Tags
IRIS
•
Molybdenum
Litsearch 2018
Pubmed
WOS
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity